WILMINGTON, N.C., May 14, 2024
/PRNewswire/ -- CardioPharma Inc. (the "Company"), a specialty
pharmaceutical company focused on drug development for
cardiovascular diseases, announced that on August 29, 2023, the United States Patent and
Trademark Office ("USPTO") issued US Patent 11,737,988 B2 entitled
"Anti-Hypertensive and Cholesterol-Lowering Fixed-Dose
Combination and Method of Manufacture." Additional patents
covering the subject matter of the '988 Patent have been granted in
South Africa in 2022 and
Australia, Armenia, Belarus,
and the Russian Federation in
2024. Three further patents have been accepted in Canada, New
Zealand, and Israel and
will issue in the near future. In addition to the
foregoing, CardioPharma is pursuing additional patents in
major markets throughout the world, all of which together will
bolster CardioPharma's global presence for the products covered by
the patent grants. The 20-year term for all of the patents runs
through April 17, 2039.
CardioPharma Pipeline
CardioPharma's pipeline products contain some of the world's
most consumed, individually dispensed medications for the
prevention and treatment of cardiovascular disease. The lead
product, CardiaPill® is a unique formulation
combining a cholesterol modifying agent ("statin"), an
Angiotensin-converting-enzyme inhibitor (ACE Inhibitor) and
anti-platelet agent. Statins moderate cholesterol levels and
include products such as Lipitor®, Zocor®,
Pravachol®; and Crestor®. ACE inhibitors
reduce blood pressure and include products such
as Altace®, Lotensin®,
Capoten® and Accupril®. Pipeline products
also include combinations using Angiotensin II Receptor
Blockers (ARBs) as well as different statins and other
anti-platelet agents. Simplicity of dosing, improved adherence and
significant cost benefits for patients, providers and payors around
the world are among the many compelling and well-documented
benefits that make these inexpensive products so anticipated.
About CardioPharma
CardioPharma (www.cardio-pharma.com), Inc. is a specialty
pharmaceutical company focused on patent-protected combinatorial
cardiovascular medications. CardioPharma's goal is to create drugs
that make it easier and more cost-effective for doctors and their
patients to reduce the morbidity and mortality of the world's
number one killer – cardiovascular disease. The products are unique
to the global pharmaceutical industry – highly cost-effective with
proven efficacy; providing both patient and provider convenience;
promoting adherence, while delivering superior clinical outcomes
and economic benefits to all stakeholders.
For more information, visit www.cardio-pharma.com.
Forward looking statements
The information in this press release contains
forward-looking statements including the prospective development,
commercialization and regulatory approval in the U.S. and
international markets. Words such as "expects," "plans," "believe,"
"may," "will," "anticipated," "intended" and variations of these
words or similar expressions are intended to identify
forward-looking statements. In addition, any statements that refer
to expectations, projections or other characterizations of future
events or circumstances, including any underlying assumptions, are
forward-looking statements. These statements are not guarantees of
future performance and are subject to risks, uncertainties and
assumptions that are difficult to predict. Therefore, our actual
results could differ materially and adversely from those expressed
in any forward-looking statements as a result of various factors
including the Company's ability to raise sufficient funds to bring
new products to the global market.
Contact: info@cardio-pharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cardiopharma-announces-issuance-of-global-patent-to-mitigate-the-worlds-top-killer-302145237.html
SOURCE CardioPharma, Inc.